查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1772409

外用藥物 CDMO 市場規模、佔有率和趨勢分析報告：按劑型、服務、最終用途、地區和細分市場預測，2025 年至 2033 年

Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Formulation (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products), By Service, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

外用藥物 CDMO 市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球局部藥物CDMO市場規模預計到2033年將達到142.2億美元，2025年至2033年期間的複合年成長率為7.5%。

針對各種皮膚相關疾病和皮膚病的專用外用藥物需求日益成長。醫療保健提供者和患者正在尋求客製化解決方案，這導致對擁有外用藥物專業知識的CDMO的需求日益成長。

市場碎片化，多家公司擁有相似的技術力和加工能力。乳化、奈米技術和經皮吸收貼片等創新藥物傳遞技術的發展，提升了CDMO開發更利於病患、更有效的外用藥物的能力。此外，個人化醫療的日益普及也顯著提升了對外用CDMO的需求，因為它們在根據患者個別情況和需求提供個人化外用藥物治療方面發揮著重要作用。

CDMO與製藥公司之間的合作日益增多，CDMO為創新型外用藥物的生產和開發做出了貢獻。製藥公司通常選擇將生產服務委託給專業的CDMO，同時專注於自身的核心競爭力，例如研發、分銷和行銷。 FDA核准的外用藥物數量和產品上市數量的不斷增加，是專門從事外用藥物生產的CDMO數量成長的主要推動力。例如，2022年5月，Dermavant Sciences公司獲得美國食品藥物管理局(FDA)核准，其1% VTAMA（tapinarof）乳膏可用於治療成人斑塊型乾癬的局部治療。

新冠疫情對市場產生了負面影響。疫情嚴重擾亂了全球供應鏈，影響了生產能力和原料供應。由於安全問題，包括外用藥物在內的多項臨床試驗被暫時推遲或擱置。這阻礙了新型外用藥物和製劑的測試和開發。然而，透過採取收購和與專業製藥商合作等策略性舉措，該產業在2021年恢復了市場佔有率。

外用藥物CDMO市場報告重點

  • 以劑型分類，半固態劑型市場在2024年的收入佔有率最高，為66.44%。該市場的成長動力源於乳膏、凝膠和軟膏需求的不斷成長，以及外用藥物臨床試驗的增加。同時，由於針對多種疾病的外用乳膏核准不斷增加，因此乳膏子類別預計將佔據相當大的佔有率。
  • 按服務分類，契約製造部門在 2024 年佔據了最大的收入佔有率。該部門佔有率高是由於對製造外包服務的需求不斷增加，這主要受到製造外包的成本效益的推動。
  • 根據最終用途，由於與外用藥物開發相關的研發活動的增加，該生物製藥公司預計將在預測期內實現最高的複合年成長率。
  • 預計亞太地區在預測期內將實現顯著的複合年成長率。該地區的顯著成長可歸因於外用產品生產成本的提高，這主要得益於多個亞洲經濟體較低的人事費用和營運成本。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章 外用藥物 CDMO 市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 技術格局
  • 定價模式分析
  • 研發成本分析（2021-2024）
  • 市場分析工具
    • 波特五力分析
    • PESTEL 與 SWOT 分析

第4章 外用藥物 CDMO 市場：以劑型進行的估算與趨勢分析

  • 外用藥物 CDMO 市場（按劑型）：細分儀表板
  • 外用藥物 CDMO 市場（按劑型）：差異分析
  • 按劑型分類，2021-2033年
  • 半固態製劑
    • 奶油
    • 軟膏
    • 凝膠
    • 其他
  • 液體製劑
  • 固態製劑
  • 經皮產品

第5章 外用藥物 CDMO 市場：依服務與趨勢分析估算

  • 外用藥物 CDMO 市場、服務細分儀表板
  • 外用藥物CDMO市場（按服務）：變化分析
  • 按服務分類，2021-2033 年
  • 合約開發
  • 契約製造

第6章 局部用藥 CDMO 市場：最終用途估算與趨勢分析

  • 外用藥物 CDMO 市場（依最終用途）：細分儀表板
  • 外用藥物 CDMO 市場（依最終用途分類）：差異分析
  • 依最終用途，2021-2033 年
  • 製藥公司
  • 生物製藥公司
  • 其他

第7章：外用藥物 CDMO 市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 2024 年及 2033 年區域市場佔有率分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與企業
  • 2024年市場分析（熱圖分析）
  • 公司簡介
    • Lubrizol Life Science
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • MedPharm Ltd
    • PCI Pharma Services

第9章 主要建議

Product Code: GVR-4-68040-150-0

Topical Drugs CDMO Market Growth & Trends:

The global topical drugs CDMO market size is expected to reach USD 14.22 billion by 2033, registering a CAGR of 7.5% from 2025 to 2033, according to a new report by Grand View Research, Inc. There is an increasing need for specialized topical drugs to address various skin-related and dermatological conditions. Healthcare providers and patients seek customized solutions, leading to a rise in demand for CDMOs with specialized expertise in topical drugs.

The market is fragmented, with several players having similar technological and processing capabilities. The development of innovative drug delivery technologies, such as microemulsions, nanotechnology, and transdermal patches, has extended the abilities of CDMOs to create more patient-friendly and effective topical drug products. Furthermore, a growing trend towards personalized medicine has significantly boosted demand for topical drug CDMOs, as they play a fundamental role in personalizing topical treatments to individual patient conditions and needs.

Collaborations between CDMOs and pharmaceutical companies have risen, with CDMOs contributing to the manufacturing and development of innovative and new topical drugs. Pharmaceutical firms significantly opt for outsourcing with an aim to focus on core competencies such as research, distribution, and marketing while entrusting manufacturing services to dedicated CDMOs. The increasing number of FDA approvals and product launches in topical medications significantly contributes to CDMOs specializing in topical drug manufacturing growth. For instance, in May 2022, Dermavant Sciences received the U.S. Food and Drug Administration (FDA) approval for its VTAMA (tapinarof) cream, 1%, for the topical management of plaque psoriasis in adults.

The COVID-19 pandemic negatively impacted the market. The pandemic has significantly disrupted the global supply chains, affecting the accessibility of manufacturing capabilities and raw materials. Several clinical studies, including those for topical medicine, were temporarily delayed or put on hold owing to safety concerns. This disturbed the testing and development of new topical drug treatments and formulations. However, by adopting strategic initiatives such as acquisition and partnerships with specialized drug providers, the industry regained its market shares by 2021.

Topical Drugs CDMO Market Report Highlights:

  • Based on formulation, the semi-solid formulations segment held the largest revenue share of 66.44% in 2024.The segment is driven by the growing demand for creams, gels, and ointments and the rise in clinical trials involving topical drugs. The cream sub-category, on the other hand, held the lion's share owing to increasing approval of topical creams for several medical conditions.
  • Based on the service, the contract manufacturing segment held the largest revenue share in 2024. The high shares of the segment are majorly due to the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing.
  • In terms of end-use, the biopharmaceutical companies segment is anticipated to witness highest CAGR during the forecast period owing to the rise in focus on R&D activities pertaining to the development of topical medication.
  • Asia Pacific is anticipated to register the significant CAGR over the forecast period. The region's substantial growth is primarily attributed to the cost-effective manufacturing of topical products due to lower labor and operational costs in several Asian economies.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Formulation
    • 1.2.2. Service
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High demand for non-invasive treatment options to boost sales of topical drugs
      • 3.2.1.2. Growing pipeline of topical drugs
      • 3.2.1.3. Growing research and development investments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. R&D Spending Analysis (2021-2024)
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Force Analysis
    • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Topical Drugs CDMO Market: Formulation Estimates & Trend Analysis

  • 4.1. Topical Drugs CDMO Market, By Formulation: Segment Dashboard
  • 4.2. Topical Drugs CDMO Market, By Formulation: Movement Analysis
  • 4.3. Topical Drugs CDMO Market Estimates & Forecasts, By Formulation, 2021 - 2033 (USD Million)
  • 4.4. Semi-solid Formulations
    • 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Creams
      • 4.4.2.1. Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Ointments
      • 4.4.3.1. Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Gel
      • 4.4.4.1. Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Liquid Formulations
    • 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Solid Formulations
    • 4.6.1. Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Transdermal Products
    • 4.7.1. Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Topical Drugs CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Topical Drugs CDMO Market, Service: Segment Dashboard
  • 5.2. Topical Drugs CDMO Market, Service: Movement Analysis
  • 5.3. Topical Drugs CDMO Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Contract Development
    • 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Topical Drugs CDMO Market, By End Use: Segment Dashboard
  • 6.2. Topical Drugs CDMO Market, By End Use: Movement Analysis
  • 6.3. Topical Drugs CDMO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biopharmaceutical Companies
    • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Topical Drugs CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2033
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. U.S
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Market Position Analysis, 2024 (Heat Map Analysis)
  • 8.3. Company Profiles
    • 8.3.1. Lubrizol Life Science
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Cambrex Corporation
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Contract Pharmaceuticals Limited
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Bora Pharmaceutical CDMO
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Ascendia Pharmaceuticals
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Pierre Fabre group
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Piramal Pharma Solutions
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. DPT Laboratories, LTD
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. MedPharm Ltd
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. PCI Pharma Services
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

Chapter 9 Key Recommendations

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 5 Global Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6 Global Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 7 Global Topical Drugs CDMO Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 8 North America Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 9 North America Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 10 North America Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 11 North America Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 12 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 13 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 14 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
  • Table 15 U.S. Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Canada Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 17 Canada Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 18 Canada Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 20 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 21 Mexico Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 22 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 23 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 24 Europe Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 25 Europe Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 27 UK Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 28 UK Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 29 Germany Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 30 Germany Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 31 Germany Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 32 France Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 33 France Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 34 France Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 35 Italy Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 36 Italy Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 37 Italy Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Spain Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 39 Spain Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 40 Spain Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 41 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 42 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 43 Denmark Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 44 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 45 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 46 Sweden Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 47 Norway Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 48 Norway Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 49 Norway Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 53 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 54 Japan Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 55 Japan Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 56 Japan Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 57 China Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 58 China Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 59 China Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 60 India Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 61 India Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 62 India Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 63 Australia Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 64 Australia Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 65 Australia Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 66 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 67 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 68 Thailand Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 69 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 70 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 71 South Korea Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 73 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 74 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 75 Latin America Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 76 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 77 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 78 Brazil Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 79 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 80 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 81 Argentina Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 84 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 85 Middle East & Africa Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 86 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 87 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 88 South Africa Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 91 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 92 UAE Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 93 UAE Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 94 UAE Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by Formulation, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 97 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 Topical Drugs CDMO Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Topical Drugs CDMO Market: Formulation outlook and key takeaways
  • Fig. 20 Topical Drugs CDMO Market: Formulation movement analysis
  • Fig. 21 Semi-solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Topical Drugs CDMO Market: Service outlook and key takeaways
  • Fig. 30 Topical Drugs CDMO Market: Service movement analysis
  • Fig. 31 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Topical Drugs CDMO Market: End Use outlook and key takeaways
  • Fig. 34 Topical Drugs CDMO Market: End Use movement analysis
  • Fig. 35 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Regional Marketplace: Key Takeaways
  • Fig. 39 North America Topical Drugs CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Spain Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 South Korea Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Brazil Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Argentina Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 South Africa Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Saudi Arabia Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 UAE Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Kuwait Topical Drugs CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key company categorization
  • Fig. 91 Service heat map analysis
  • Fig. 92 Strategic framework